Takeda Pharmaceutical Net Income 2007-2019 | TAK

Takeda Pharmaceutical annual/quarterly net income history and growth rate from 2007 to 2019. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Takeda Pharmaceutical net income for the quarter ending September 30, 2019 was $0.501B, a 61.57% decline year-over-year.
  • Takeda Pharmaceutical net income for the twelve months ending September 30, 2019 was $1.369B, a 154.32% increase year-over-year.
  • Takeda Pharmaceutical annual net income for 2019 was $0.982B, a 41.61% decline from 2018.
  • Takeda Pharmaceutical annual net income for 2018 was $1.682B, a 57.35% increase from 2017.
  • Takeda Pharmaceutical annual net income for 2017 was $1.069B, a 60.65% increase from 2016.
Takeda Pharmaceutical Annual Net Income
(Millions of US $)
2019 $982
2018 $1,682
2017 $1,069
2016 $665
2015 $-1,327
2014 $1,067
2013 $1,588
2012 $1,577
2011 $2,986
2010 $3,202
2009 $2,392
2008 $3,555
2007 $2,846
2006 $2,677
Takeda Pharmaceutical Quarterly Net Income
(Millions of US $)
Q2 2019 $501
Q1 2019 $-188
Q3 2018 $336
Q1 2018 $720
Q1 2017 $1,303
Q1 2016 $926
Q1 2015 $202
Q4 2015 $-1,892
Q3 2014 $156
Q2 2014 $260
Q1 2014 $326
Q4 2014 $-43
Q3 2013 $457
Q2 2013 $360
Q1 2013 $296
Q4 2013 $462
Q3 2012 $236
Q2 2012 $409
Q1 2012 $1,119
Q4 2012 $-460
Q3 2011 $322
Q2 2011 $775
Q4 2011 $394
Q4 2010 $426
Q2 2009 $-1
Q4 2009 $705
Q4 2008 $-922
Q4 2007 $583
Q4 2006 $275
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $62.561B $18.875B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $58.852B 35.20
Astellas Pharma (ALPMY) Japan $32.261B 16.11
Eisai (ESALY) Japan $20.942B 40.38
Grifols, S.A (GRFS) Spain $15.594B 20.43
UCB SA (UCBJF) Belgium $15.483B 0.00
Merck (MKGAF) Germany $14.630B 19.97
Neurocrine Biosciences (NBIX) United States $10.430B 492.39
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Ionis Pharmaceuticals (IONS) United States $8.678B 17.58
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.638B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $8.380B 10.70
Catalent (CTLT) United States $7.634B 31.06
IPSEN SA ADR (IPSEY) France $7.374B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $6.529B 98.87
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.226B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
STADA ARZNEIMI (STDAF) Germany $5.375B 0.00
Hypermarcas (HYPMY) Brazil $4.932B 17.73
FibroGen (FGEN) United States $4.127B 121.28
United Therapeutics (UTHR) United States $4.059B 0.00
Nektar Therapeutics (NKTR) United States $3.800B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.641B 13.31
Sage Therapeutics (SAGE) United States $3.558B 0.00
Evotec AG (EVTCY) Germany $3.498B 57.24
PTC Therapeutics (PTCT) United States $2.966B 0.00
ArQule (ARQL) United States $2.439B 0.00
Heron Therapeutics (HRTX) United States $2.304B 0.00
Xencor (XNCR) United States $2.160B 65.65
Portola Pharmaceuticals (PTLA) United States $2.113B 0.00
Zogenix (ZGNX) United States $2.093B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.943B 61.95
Pacira Pharmaceuticals (PCRX) United States $1.900B 56.22
Tilray (TLRY) Canada $1.829B 0.00
ChemoCentryx (CCXI) United States $1.812B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.741B 0.00
USANA Health Sciences (USNA) United States $1.621B 17.30
Corcept Therapeutics (CORT) United States $1.551B 18.85
Enanta Pharmaceuticals (ENTA) United States $1.268B 28.95
CLINIGEN GP (CLIGF) United Kingdom $1.245B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.176B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.130B 0.00
Karyopharm Therapeutics (KPTI) United States $1.049B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.041B 7.10
Radius Health (RDUS) United States $1.019B 0.00
Endo (ENDP) Ireland $0.996B 1.83
Aerie Pharmaceuticals (AERI) United States $0.993B 0.00
Flexion Therapeutics (FLXN) United States $0.794B 0.00
Akebia Therapeutics (AKBA) United States $0.747B 0.00
Collegium Pharmaceutical (COLL) United States $0.684B 0.00
TherapeuticsMD (TXMD) United States $0.643B 0.00
Dermira (DERM) United States $0.636B 0.00
ImmunoGen (IMGN) United States $0.545B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.530B 0.00
Translate Bio (TBIO) United States $0.508B 0.00
Ardelyx (ARDX) United States $0.472B 0.00
Organogenesis Holdings (ORGO) United States $0.461B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.443B 53.75
Aptorum Group (APM) Hong Kong, SAR China $0.442B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.435B 18.74
Harpoon Therapeutics (HARP) United States $0.431B 0.00
Molecular Templates (MTEM) United States $0.412B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.410B 0.00
OptiNose (OPTN) United States $0.394B 0.00
Indivior (INVVY) United States $0.389B 1.41
Rigel Pharmaceuticals (RIGL) United States $0.382B 0.00
Siga Technologies (SIGA) United States $0.379B 8.65
Recro Pharma (REPH) United States $0.378B 0.00
DURECT (DRRX) United States $0.367B 0.00
Innate Pharma SA (IPHYF) France $0.358B 0.00
Lannett Co Inc (LCI) United States $0.354B 4.12
Corbus Pharmaceuticals Holdings (CRBP) United States $0.318B 0.00
Jounce Therapeutics (JNCE) United States $0.304B 4.06
Rafael Holdings (RFL) United States $0.303B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.285B 0.00
KalVista Pharmaceuticals (KALV) United States $0.276B 0.00
Concordia (CXRXF) Canada $0.269B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.267B 0.00
Calithera Biosciences (CALA) United States $0.243B 0.00
GlycoMimetics (GLYC) United States $0.242B 0.00
Xeris Pharmaceuticals (XERS) United States $0.241B 0.00
Aquestive Therapeutics (AQST) United States $0.193B 0.00
Ocular Therapeutix (OCUL) United States $0.192B 0.00
Nature's Sunshine Products (NATR) United States $0.191B 32.93
AcelRx Pharmaceuticals (ACRX) United States $0.190B 0.00
Concert Pharmaceuticals (CNCE) United States $0.188B 0.00
Taiwan Liposome (TLC) Taiwan $0.178B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.170B 0.00
IMV INC (IMV) Canada $0.157B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.146B 0.00
MEI Pharma (MEIP) United States $0.144B 0.00
Redhill Biopharma (RDHL) Israel $0.136B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.130B 0.00
CannTrust Holdings (CTST) Canada $0.116B 0.00
CV Sciences (CVSI) United States $0.111B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.094B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.088B 0.00
Capnia (SLNO) United States $0.084B 0.00
MediWound (MDWD) Israel $0.082B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.079B 23.64
Otonomy (OTIC) United States $0.077B 0.00
Champions Oncology (CSBR) United States $0.077B 0.00
Aclaris Therapeutics (ACRS) United States $0.075B 0.00
Neos Therapeutics (NEOS) United States $0.074B 0.00
PolarityTE (PTE) United States $0.073B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.071B 0.00
CTI BioPharma (CTIC) United States $0.070B 0.00
Infinity Pharmaceuticals (INFI) United States $0.067B 0.00
Nivalis Therapeutics (ALPN) United States $0.067B 0.00
Pharmaxis (PXSLY) Australia $0.065B 0.00
Forward Pharma (FWP) Denmark $0.065B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.063B 0.00
RENEURON GP (RNUGF) United Kingdom $0.062B 0.00
Genocea Biosciences (GNCA) United States $0.059B 0.00
Novan (NOVN) United States $0.059B 0.00
Natural Alternatives (NAII) United States $0.057B 14.29
Opiant Pharmaceuticals (OPNT) United States $0.057B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.056B 0.00
Medicure (MCUJF) Canada $0.055B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.053B 0.00
Mast Therapeutics (SVRA) United States $0.050B 0.00
AgeX Therapeutics (AGE) United States $0.049B 0.00
SCYNEXIS (SCYX) United States $0.046B 0.00
ElectroCore (ECOR) United States $0.046B 0.00
Iterum Therapeutics (ITRM) Ireland $0.044B 0.00
IsoRay (ISR) United States $0.042B 0.00
Opexa Therapeutics (ACER) United States $0.040B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.038B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.032B 0.00
Jaguar Animal Health (JAGX) United States $0.030B 0.00
PharmAthene (ALT) United States $0.028B 0.00
Shineco (TYHT) China $0.028B 0.00
India Globalization Capital (IGC) United States $0.027B 0.00
Biomerica (BMRA) United States $0.026B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.026B 0.00
ProPhase Labs (PRPH) United States $0.023B 0.00
Cardiome Pharma (CORV) Canada $0.023B 0.00
Bio-Path Holdings (BPTH) United States $0.022B 0.00
China SXT Pharmaceuticals (SXTC) China $0.022B 0.00
Melinta Therapeutics (MLNT) United States $0.022B 0.00
Heat Biologics (HTBX) United States $0.016B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.016B 0.00
Flex Pharma (SLRX) United States $0.015B 0.00
VAXART, INC (VXRT) United States $0.015B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Vical (BBI) United States $0.013B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Lipocine (LPCN) United States $0.009B 0.00
HANCOCK JAFFE (HJLI) United States $0.008B 0.00
Achieve Life Sciences (ACHV) United States $0.007B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.006B 0.00
RXi Pharmaceuticals (PHIO) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Can-Fite Biopharma (CANF) Israel $0.004B 0.00
Hemispherx BioPharma (AIM) United States $0.003B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00
Onconova Therapeutics (ONTX) United States $0.002B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00